Antoni van Leeuwenhoek
Amsterdam, North Holland, 1066CX, Netherlands
Location status: Recruiting
Location contact
Ingrid Mandjes
CONTACT
Sabine Linn, MD
PRINCIPAL_INVESTIGATOR
Sarah Pruckl, PhD
CONTACT
NCT Number: NCT06273800
This study is a prospective, multicenter study in which a serum sample will be collected at the day of starting neo adjuvant treatment in breast cancer patients
Interested in participating?
Request Info18 year–59 year
Female
Interventional
Not applicable
Amsterdam, North Holland, 1066CX, Netherlands
Location status: Recruiting
Ingrid Mandjes
CONTACT
Sabine Linn, MD
PRINCIPAL_INVESTIGATOR
Sarah Pruckl, PhD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Collection of serum sample at the day of start of neo adjuvant treatment
Time frame: At 6 months
Number of patients achieving a pathological complete response
Time frame: At 6 months
Number of patients achieving a radiological response (CR, PR, SD) based on MRI after neo adjuvant treatment
Time frame: At 6 months
Number of patients achieving a pathological response (CR, PR, SD) based on pathology report after neo adjuvant
Time frame: At 6 months
quantificaton of the residual disease after neoadjuvant therapy
Time frame: Up to 120 months
Number of patients with distant recurrence
Time frame: Up to 120 months
Number of patients with disease recurrence
Time frame: Up to 120 months
Number of patients alive or deceased
Contact information is provided by the study sponsor or research team.
The Netherlands Cancer Institute
Other
Acronym: Chemosense
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04816006
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phoenix, Arizona, United States
View Trial DetailsNCT05625659
Breast Cancer, Breast Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06954337
Breast Cancer, Breast Diseases
Basking Ridge, New Jersey, United States
View Trial DetailsNCT07340541
Breast Cancer, Breast Diseases
Baltimore, Maryland, United States
View Trial Details